HALO
#826
Halozyme Therapeutics, Inc. - Common Stock
105.3 5 USD
-0.01%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
Year Range
Daily Change
-1.47%
Monthly Change
+26.64%
6 month change
+54.19%
Year Change
+57.71%
Previous Close
106.9 2
Open
105.3 5
Low
105.3 5
High
105.3 5
Volume
139
Financials
- Market Capitalization 11.96 B
- Employee 423
- Founded 1998
- CEO Helen I. Torley
- Website www.halozyme.com
- Headquarter Delaware, United States
- FIGI BBG000CZ8W54
- Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
26.29
Price to sales ratio
5.97
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 810 |  CORT Corcept Therapeutics Incorporated - Common Stock | 113.88 USD | -2.61% | -5.54% | -3.57% | +55.21% | 12.31 B USD | ||
| 823 |  ARWR Arrowhead Pharmaceuticals, Inc. - Common Stock | 84.91 USD | -4.15% | -2.14% | -2.32% | +117.16% | 11.99 B USD | ||
| 852 |  TECH Bio-Techne Corp - Common Stock | 72.35 USD | -0.17% | +0.11% | +0.42% | +33.56% | 11.35 B USD | ||
| 870 |  SMMT Summit Therapeutics Inc. - Common Stock | 13.73 USD | -4.19% | +5.05% | +2.16% | -30.87% | 10.95 B USD |
Frequently asked questions about Halozyme Therapeutics, Inc.
What is the Halozyme Therapeutics, Inc. stock price today?
The current price of Halozyme Therapeutics, Inc. (HALO) is 105.35. Over the past 24 hours, the stock has changed by -1.47%. Follow the HALO chart for real-time price dynamics.
What is the stock ticker of Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. trades under the ticker HALO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Halozyme Therapeutics, Inc. stock going up?
HALO has changed by -2.53% over the last week, +26.64% over the last month, and +57.71% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. currently has a market capitalization of 11.96 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Halozyme Therapeutics, Inc. earnings last quarter?
Last quarter, Halozyme Therapeutics, Inc. reported earnings of 1.96 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Halozyme Therapeutics, Inc. revenue for the last quarter?
Halozyme Therapeutics, Inc. reported quarterly revenue of 481 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Halozyme Therapeutics, Inc. net income for the last quarter?
Halozyme Therapeutics, Inc. reported net income of 229.91 M for the last quarter. The previous quarter showed 150.05 M, which means net income changed by +53.23%.
How many employees does Halozyme Therapeutics, Inc. have?
As of the latest available data, Halozyme Therapeutics, Inc. has 423 employees. Workforce size can provide additional context about the company's scale and operations.
What is Halozyme Therapeutics, Inc. EBITDA?
Halozyme Therapeutics, Inc. EBITDA is 292.15 M, and its EBITDA margin is 60.74%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Halozyme Therapeutics, Inc. stock?
You can buy Halozyme Therapeutics, Inc. (HALO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Halozyme Therapeutics, Inc. stock?
Investing in Halozyme Therapeutics, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the HALO chart and related analysis on metatrader.com as part of your research.